Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark Authors: Lene von Kappelgaard, Elisabeth Framke, Ditte Vassard, Anja Pinborg, Juan Enrique Schwarze, Meritxell Sabidó, Melinda Magyari Published: 2025 ABSTRACT AbstractBackgroundEvidence on relapse activity in relapsing-remitting multiple sclerosis (RRMS) after assisted reproductive technology (ART) treatment differs. We investigated whether relapse activity increased after ART initiation.MethodsWomen with RRMS from the Danish MS Registry who underwent ART treatment from 1995 to 2018 were eligible. The annualised relapse rate (ARR) and corresponding 95% CI at 3 and 9 months post-ART initiation versus 12 months pre-ART were investigated using a negative binomial regression model. Analyses were stratified for live births within 12 months post-ART and disease-modifying therapy (DMT) use pre-ART. Clinical and demographic factors associated with relapse risk were identified.ResultsAt ART initiation, 162 women, median age 33 years (IQR: 30–37), median Expanded Disability Status Scale score 1.5 (IQR: 1.0–2.5) were included; 55 (34.0%) were exposed to DMT. 27 relapses were recorded (ARR (95% CI) 0.17 (0.11 to 0.26)) at 12 months pre-ART; 7 relapses and 0.17 (0.08 to 0.36) at 3 months post-ART initiation, and 16 relapses and 0.13 (0.08 to 0.23) at 9 months post-ART initiation. When stratified by ART outcomes, relapse counts in subgroups became small. Women continuing DMT at ART initiation showed a statistically non-significant increase in ARR at 3 months post-ART.ConclusionsWomen with RRMS in Denmark did not, on average, have increased relapse activity at 3 and 9 months post-ART initiation compared with 12 months pre-ART. Women with disease activity pre-ART initiation may have a potentially elevated relapse risk post-ART.Keywords: MULTIPLE SCLEROSIS, NEUROIMMUNOLOGY, EPIDEMIOLOGY, OBSTETRICS WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS Women with relapsing-remitting multiple sclerosis (RRMS) in Denmark did not, on average, have increased relapse activity at 3 and 9 months post-ART initiation compared with 12 months pre-ART initiation; however, relapse risk may be elevated post-ART initiation in women with disease activity pre-ART. Among women continuing DMT at ART initiation, a statistically non-significant increase in the relapse rate was observed at 3 months post-ART initiation. Women with relapsing-remitting multiple sclerosis (RRMS) in Denmark did not, on average, have increased relapse activity at 3 and 9 months post-ART initiation compared with 12 months pre-ART initiation; however, relapse risk may be elevated post-ART initiation in women with disease activity pre-ART. Among women continuing DMT at ART initiation, a statistically non-significant increase in the relapse rate was observed at 3 months post-ART initiation. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study may help guide the management of women with RRMS who are planning a pregnancy, particularly in balancing MS disease with the desire to optimise their chances of conception. This study may help guide the management of women with RRMS who are planning a pregnancy, particularly in balancing MS disease with the desire to optimise their chances of conception. Introduction Multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, affects more women than men,1 and it is often diagnosed during reproductive age.2 The characteristics of MS and the use of disease-modifying therapies (DMTs) for MS management may affect family planning decision-making.3 4 Women with MS may also have decreased fertility and fewer children,5,7 which means that assisted reproductive technology (ART) treatment may be sought to give them an increased chance of pregnancy. It has been reported that the proportion of women with MS seeking such treatment is increasing.8 This is of potential concern as ART treatment may lead to an increase in relapse rate and MS activity.9,13 For example, in a pooled analysis of four patient cohorts including 164 individual ART cycles, the annualised relapse rate (ARR) was significantly higher in the 3 months following ART compared with the preceding 12 months, although the effect was not consistent across all cohorts included in the analysis—the Boston cohort, which considered 22 ART cycles, showed no increase in the relapse rate in the 3 months after ART.14 Further, recent evidence based on larger study populations did not find any statistically significant increase in the relapse risk.15 16 Additionally, a study on a small population has recently shown no significant increase in relapse rate within a year of ART.17 Thus, the direction and magnitude of the effect of ART on relapse activity remain unclear. The modern ART process for women with MS is not dissimilar to that for women without MS. Two main options are available, namely artificial insemination, most commonly intrauterine insemination (IUI), and in vitro fertilisation (IVF) which includes intracytoplasmic sperm injection (ICSI). In Denmark, women younger than 41 years of age are offered, within the National Health Programme, up to three completed IVF or ICSI transfer cycles or oocyte recipient cycles with fresh embryos and an unrestricted number of cycles with frozen/thawed embryo transfer (ET); and IUI with partner or donor semen (in practice up to three to six cycles). Private fertility clinics offer ART treatment to women over 41 years of age, although Danish law does not permit treatment over the age of 45 years. The IVF process involves controlled ovarian stimulation (COS) with gonadotropin-releasing hormone (GnRH) agonists and antagonists, but the preferred method of COS is now regarded to be via GnRH antagonists.8 Our study aimed to investigate whether clinical disease activity after ART treatment initiation was higher than that before ART treatment in a nationwide population of women with relapsing-remitting MS undergoing ART in Denmark. In our study, we hypothesised that average clinical disease activity would be higher after ART initiation and a high proportion of women would have an increase in relapse activity after ART initiation. We further identified the clinical and demographical factors associated with the subsequent risk of clinical disease activity. Materials and methods Study population and data sources This nationwide and population-based cohort study included women with relapsing-remitting MS from the Danish Multiple Sclerosis Registry (DMSR) who underwent ART treatment between 1995 and 2018, were aged 18–45 years and had MS disease duration of ≥12 months at the time of first ART treatment. Linkage of individual information with other population-based registries and the following data sources was used in this study: the DMSR,18 the Danish Civil Registration System19 and the Danish National Patient Registry,20 the Danish National Register of ART (encompassing the Danish IVF register)21 and the Danish Medical Birth Register.22 Since 1996, it has been mandatory in Denmark to collect in the DMSR all information on MS demographic and clinical characteristics and DMTs used. From 2006 onwards, all medically assisted reproduction treatments (including IUI) are recorded in the Danish National Register of ART, whereas only ART treatments were included during the first registration phase (1994–2006). Similarly, it is mandatory under Danish law for all fertility clinics to report to the Danish National Register of ART. Study design An ART cycle was defined as an ovarian stimulation (OS) cycle initiated with the intention to retrieve multiple oocytes, fertilise the oocytes using IVF (with or without ICSI) and perform fresh ET and/or frozen-thawed ET. The first ART cycle initiated was used for this analysis. Initiation of ART treatment was defined as the first day of administration of hormones for OS, and the observation period for each woman started from this date in the ART registry. The end of the observation period was the end of the study (2021), emigration or death, whichever occurred first. The use of DMT pre-ART initiation was categorised according to whether the patient was DMT-treatment naïve pre-ART initiation (ie, there was no recorded use of DMTs), DMT was discontinued pre-ART initiation or DMT was continued at ART initiation. Types of DMT were categorised as injectables (including glatiramer acetate, interferons and ofatumumab); orals (including cladribine tablets, fingolimod, fumarates, ozanimod, ponesimod, siponimod and teriflunomide) and infusions (including alemtuzumab, natalizumab, ocrelizumab and rituximab). Details of the GnRH stimulation protocol employed (ie, agonist or antagonist) were only available from 2006 to 2018. Outcomes The number of relapses, when new symptoms appeared or existing symptoms worsened, for a period of 24 hours or more, was recorded in the clinical data platform by the treating neurologist. The term clinical disease activity covers relapses, while disease activity covers relapses and/or radiological activity. Data on relapses for the 12-month period before the first ART initiation, as well as at 3 and 9 months following the first ART initiation (herein referred to as post-ART initiation), were included in the analyses. Data on ART success (live birth(s)) or ART failure (no live birth) within 12 months of the first ART cycle were also included. Additional outcomes evaluated included the time to first relapse after the first ART initiation, with a follow-up time of 3 months post-ART initiation. In analyses of time to first relapse, disease activity was defined as radiological activity and/or relapse within 14 months pre-ART initiation (a time period of 14 months was used to allow for completion of MRI data). Statistical methods All variables were summarised descriptively. Categorical data were summarised as the number and percentage of patients, and continuous data as the mean, SD, median and IQR (Q1–Q3). The population ARRs within 12 months pre-ART initiation and in the 3 and 9 months post-ART initiation were calculated. The population ARR and corresponding 95% CIs were estimated using a negative binomial regression model with relapse count as the dependent variable. The natural logarithm of time under observation (in years) was the offset variable in the model. Relapses were counted for the defined time period if the date of onset of the relapse was during the defined time period. The ARRs, with 95% CI, were stratified by ART success or failure. Additionally, the results were stratified by DMT use pre-ART initiation. The difference between the ARRs was also estimated using a negative binomial regression model. An additional analysis was performed of predictors of relapse activity in the 3 months post-ART initiation and was expressed as an HR, with 95% CI, using a Cox regression model. For the Cox model of time to first relapse, follow-up time was censored at death, emigration, end of follow-up, at time of first relapse or at time of the last menstrual period (LMP) for women who became pregnant, whichever came first. All statistical analyses were conducted using SAS software, V.9.4 or higher. Results Patient characteristics A total of 77 545 women living in Denmark were recorded in the ART registry between 1994 and 2018, of whom 74 612 initiated their first ever ART cycle with one or several OS between 1995 and 2018 (online supplemental material figure 1). The number of women with MS aged 18–45 years at the start of ART treatment was 195, of whom 162 had a confirmed diagnosis of relapsing-remitting MS (table 1). At the start of ART treatment, the median age (IQR) was 33 (30–37) years, and the mean duration of MS (±SD) was 7.7 (4.5) years. In the 12 months pre-ART initiation, most women (n=140, 86.4%) did not have any MS relapses, and the population ARR (95% CI) was 0.17 (0.11 to 0.26). The median (IQR) Expanded Disability Status Scale score closest to ART initiation was 1.5 (1.0 to 2.5). Overall, 61/162 (37.7%) women were DMT-treatment naïve before ART. Of the women using DMT pre-ART initiation (n=101, 62.3%), 46 (45.5%) women discontinued their DMT, of whom 37 (22.8%) discontinued >3 months pre-ART initiation, and 55 women (54.5%) continued their DMT after initiating ART. Most of these women (n=77, 76.2%) used an injectable DMT pre-ART initiation; 14/101 (13.9%) women used an infusion DMT, and 10/101 (9.9%) women used an oral DMT (table 2). Interferon beta-1a was used by approximately half of the women using a DMT (n=56, 55.4%), with natalizumab and glatiramer acetate (n=11, 10.9% each) and interferon beta-1b (n=9, 8.9%) comprising the other major DMTs used (online supplemental material table 1). A total of 19 women received DMT during pregnancy, of whom 15 discontinued their DMT during pregnancy, and four continued their DMT throughout the pregnancy. Of the 15 women discontinuing DMT during pregnancy, there was a mean (±SD) of 35 (25) days from LMP to DMT discontinuation, with all but four discontinuing within 3 months after LMP (online supplemental material table 1). Table 1Characteristics of women with relapsing-remitting MS from the Danish MS RegistryCharacteristicsWomen (N=162)Age at ART initiation, median (IQR), years33 (30–37)Duration of MS at ART initiation, mean (±SD) years7.7 (4.5)ARR (model based) for 12 months pre-ART initiation, mean (95% CI)0.17 (0.11 to 0.26)Number of relapses in the 12 months pre-ART initiation, n (%) 0140 (86.4) 119 (11.7) ≥23 (1.9)EDSS closest to ART initiation*, median (IQR)1.5 (1.0–2.5)DMT history pre-ART initiation, n (%) DMT-treatment naïve†61 (37.7) DMT discontinued >3 months pre-ART initiation37 (22.8) DMT discontinued <3 months pre-ART initiation9 (5.6) DMT continued at ART initiation55 (34.0)GnRH stimulation protocol‡, n (%) Agonist31 (26.5) Antagonist41 (35.0) Missing45 (38.5)*n=110.†DMT-treatment naïve women had no record of receiving DMT prior to ART initiation.‡Only available for 2006–2018.ARR, annualised relapse rate; ART, assisted reproductive technology; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; GnRH, gonadotropin-releasing hormone; MS, multiple sclerosis. Characteristics of women with relapsing-remitting MS from the Danish MS Registry n=110. DMT-treatment naïve women had no record of receiving DMT prior to ART initiation. Only available for 2006–2018. ARR, annualised relapse rate; ART, assisted reproductive technology; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; GnRH, gonadotropin-releasing hormone; MS, multiple sclerosis. Table 2DMT use by women with relapsing-remitting MS pre-ART initiation (N=162)DMT useWomen, n/N (%)No DMT61/162 (37.7)DMT101/162 (62.3) Injectable77/101 (76.2) Infusion14/101 (13.9) Oral10/101 (9.9)ART, assisted reproductive technology; DMT, disease-modifying therapy; MS, multiple sclerosis. DMT use by women with relapsing-remitting MS pre-ART initiation (N=162) ART, assisted reproductive technology; DMT, disease-modifying therapy; MS, multiple sclerosis. ART cycles The median (IQR) number of ART cycles was 2 (1–3). An agonist stimulation protocol was used for 31 (26.5%) women, and an antagonist stimulation protocol was used for 41 (35.0%) women, with an unknown method used for 45 women (38.5%). This information was only available between 2006 and 2018. Relapse outcomes For all women (N=162), the raw number of relapses experienced in the 12 months pre-ART initiation was 27. Following ART initiation, the raw number of relapses experienced was seven and 16 in the 3 and 9 months post-ART initiation, respectively. The ARRs in the 12 months pre-ART initiation and at 3 and 9 months post-ART initiation are shown in figure 1 and online supplemental material table 2. For the total population, the ARR (95% CI) was 0.17 (0.11 to 0.26) at 12 months pre-ART initiation, 0.17 (0.08 to 0.36) at 3 months post-ART initiation and 0.13 (0.08 to 0.23) at 9 months post-ART initiation. The difference (rate ratio) in ARR (95% CI) between 12 months pre-ART and 3 months post-ART initiation was 1.04 (0.47 to 2.32), and between 12 months pre-ART and 9 months post-ART initiation was 0.79 (0.41 to 1.55) (online supplemental material table 3). ARRs before and after ART initiation in all women and by ART outcome. *The results for 3 months post-ART cannot be stratified for success/failure due to data protection regulations; there were <3 relapses (ie, only one or two relapses) in the ART success group. †Estimates cannot be calculated due to data protection regulations because of the risk of back-calculation to another value of <3 relapses. ARR, annualised relapse rate; ART, assisted reproductive technology. In the 49 women with successful ART outcomes within 12 months of first ART initiation, the ARR (95% CI) was 0.12 (0.05 to 0.30) at 12 months pre-ART initiation; ARR was not estimatable at 3 months post-ART initiation due to data protection regulations (ie, there were <3 relapses (1 or 2 relapses)), and it was 0.08 (0.03 to 0.24) at 9 months post-ART initiation. The difference (rate ratio) in ARR (95% CI) between 12 months pre-ART initiation and 9 months post-ART initiation was 0.67 (0.22 to 2.07) (online supplemental material table 3). In the 113 women with ART failure within 12 months after first ART initiation, the ARR (95% CI) was 0.19 (0.11 to 0.31) at 12 months pre-ART initiation and 0.16 (0.09 to 0.28) at 9 months post-ART initiation; the ARR was not evaluable at 3 months post-ART initiation (online supplemental material table 2). The difference (rate ratio) in ARR (95% CI) between 12 months pre-ART initiation and 9 months post-ART initiation was 0.83 (0.38 to 1.83) (online supplemental material table 3). The ARRs pre-ART and post-ART initiation in all women with relapsing-remitting MS and according to DMT history pre-ART are shown in online supplemental material table 4. In treatment-naïve women, at 9 months post-ART initiation, the ARR (95% CI) was 0.07 (0.02 to 0.21). Data were not estimatable at 12 months pre-ART initiation and at 3 months post-ART initiation in this group. For patients who discontinued DMT before ART initiation, the ARR (95% CI) was 0.09 (0.03 to 0.28) at 9 months post-ART initiation. Data were not estimatable at 12 months pre-ART initiation and at 3 months post-ART initiation in this group. For patients who continued DMT at ART initiation, the ARR (95% CI) was 0.31 (0.18 to 0.53) in the 12 months pre-ART initiation, 0.36 (0.15 to 0.87) at 3 months post-ART initiation and 0.24 (0.13 to 0.45) at 9 months post-ART initiation. For these patients, the difference (rate ratio) between ARR (95% CI) at 12 months pre-ART initiation and 3 and 9 months post-ART initiation was 1.18 (0.47 to 2.92) and 0.78 (0.38 to 1.63), respectively (online supplemental material table 5). Relapse risk Relapse risk, as measured by time to first relapse after ART initiation, is shown in table 3. Disease activity before ART initiation was associated with a HR of 4.45 although this was statistically non-significant (95% CI 0.94 to 21.04, p=0.06). A 1-year increase in age and being treatment naïve was associated with protective, but statistically non-significant HRs. Table 3Relapse risk measured as time to first relapse after first ART initiation during up to 3 months of follow-up*†CovariateHR95% CIp valueAge (continuous)0.930.79 to 1.080.33DMT-treatment naïve before ART0.440.05 to 3.980.47Disease activity‡ before ART4.450.94 to 21.040.06*N=162; number of relapses=7; total time at risk=11 486.75 days.†Follow-up time was censored at death, emigration, end of follow-up (3 months after ART initiation), at time of first relapse or at time of LMP for women who became pregnant, whichever came first. The proportional hazards assumption was held.‡Disease activity is based on radiological activity and/or relapse activity within 14 months pre-ART.ART, assisted reproductive technology; DMT, disease-modifying therapy; LMP, last menstrual period Relapse risk measured as time to first relapse after first ART initiation during up to 3 months of follow-up*† N=162; number of relapses=7; total time at risk=11 486.75 days. Follow-up time was censored at death, emigration, end of follow-up (3 months after ART initiation), at time of first relapse or at time of LMP for women who became pregnant, whichever came first. The proportional hazards assumption was held. Disease activity is based on radiological activity and/or relapse activity within 14 months pre-ART. ART, assisted reproductive technology; DMT, disease-modifying therapy; LMP, last menstrual period Discussion The findings from this nationwide population-based Danish cohort study found no statistically significant difference in ARR post-ART initiation versus pre-ART initiation. Such findings are consistent with the outcomes recently described by Mainguy et al, Graham et al and Arabipoor et al,15,17 but not with earlier reports (2006–2012),9,13 which described an increase in ARR following fertility treatment. Indeed, the latest conference proceedings reporting real-world studies on the influence of ART on relapses have now consistently reported no increased relapse risk after ART initiation. In 46 women with relapsing-remitting MS and 101 ART cycles from an MS unit in Spain, the ARR was stable after ART (for unsuccessful pregnancy outcomes) and reduced when pregnancy was achieved.23 In a study of 270 ART stimulations in 91 women, 93.4% of whom had relapsing-remitting MS, from the German MS and Pregnancy Registry, ART was not associated with an increased relapse risk, and maintaining DMT during ART was associated with a reduction in the relapse risk.24 25 The Cox regression analysis in our study showed a non-significant tendency towards a higher relapse risk after ART initiation for those with higher disease activity before ART. While this did not reach statistical significance, the result is in line with the findings of Mainguy et al,16 and supports the clinical practice of recommending achievement of stable disease prior to conception where possible. The relapse risk was found to be unaffected by DMT-treatment naïve status before ART initiation in our study. Although there was a tendency towards a lower relapse risk per unit increase in age, there was little variation in the age variable in our data and the sample size for this variable was too small to become statistically significant. Increasing age and remaining on DMT was associated with a lower relapse risk in the studies by Mainguy et al16 and Graham et al.15 Maintaining DMT during ART was found to be the only factor associated with a reduction in the relapse risk as described by Range et al.24 When comparing the proportion of women with higher, lower and stable relapse activity 3 months post-ART initiation (annualised 3-month post-ART data) with the 12 months pre-ART initiation, we found that relapse activity remained stable (n=133, 82.1%) or decreased (n=22, 13.6%) in the majority of women (95.7%). Only seven (4.3%) women experienced relapse activity in the 3 months post-ART initiation compared with pre-ART initiation. This individual-level analysis of disease activity change was limited by the unequal observation windows before and after ART. Nevertheless, the chosen time frames are clinically relevant as women are generally advised to plan pregnancy, if possible, following a relapse-free year; relapses in the year before conception are associated with a higher risk of postpartum relapses.26 Moreover, concern about disease activity is greatest during the first 3 months after ART. Despite the statistical limitations, this analysis provides important information to clinicians on the proportion of women experiencing relapses in this critical period. The findings of a recently published update on pregnancy and reproductive health concluded that continuing DMTs during ART and before pregnancy can reduce relapse risk.27 In our study, 101 (62%) women had a history of DMT treatment pre-ART initiation, around half of whom (55 women) continued their DMT at the initiation of ART. By comparison, 43% of women showed recent or ongoing DMT use pre-ART initiation in the study by Graham et al15; 25% of women were using DMT at the time of IVF in the study by Mainguy et al16; DMT use continued in 67% of ART stimulations in Range et al24; and all women ceased DMT 3 months prior to IVF in the study by Arabipoor et al.17 In our study, there were no clear differences in the ARR post-ART versus pre-ART initiation when stratified by DMT use, as observed for those women who continued their DMT at ART initiation. Women who continued their DMT showed a slightly higher ARR at 9 months post-ART initiation compared with those who did not receive a DMT or discontinued before the initiation of ART. This could potentially relate to higher underlying disease activity in these individuals. At ART initiation, a total of 11 women were receiving natalizumab, of whom 8 women continued during ART and 3 women discontinued. Of the 3 women who discontinued natalizumab, they did so more than 70 days before ART initiation. Of the 4 women treated with fingolimod, none of them continued their treatment during ART. For these women who discontinued natalizumab or fingolimod, there was a rebound relapse risk. As very few women discontinued their DMT within the time period with risk of rebound, the exact numbers were not available due to data protection regulations. However, our findings suggested that rebound activity did not contribute to the reported relapse rates. Overall, the ARR data do not suggest that there was significant reactivation of disease following ART initiation. At present, it is generally agreed that, for women with MS, the increased risk of relapses with the suspension of DMT use is outweighed by the potential impact on ART outcomes. The choice of DMT must be compatible with pregnancy and should be guided on a case-by-case basis.28 The DMT treatment effect may have impacted the conclusions that can be drawn from the results generated by our study. A decrease in ARR would be anticipated during pregnancy. Indeed, Graham et al demonstrated a statistically significant decrease in relapse rates measured 3 months after fertility treatment (ie, COS and ET or ET alone) versus the measurement at 12 months before any fertility treatment in women who achieved pregnancy, with the decrease in relapse similar to that observed with a spontaneous pregnancy.15 In one study, ART failure, with no live birth within 12 months of the first ART treatment, was shown to result in a decrease in sex hormones analogous to that experienced during the postpartum period,28 and this may partly explain the increased relapse rate that was observed after IVF in the study by Michel et al.13 However, in our study, no difference in ARR was apparent between successful and failed ART treatments in the 9 months post-ART initiation. In comparison, the ARR was reduced in the 12 months after ART when pregnancy was achieved in the study by Romero-Pinel et al23; however, pregnancy was not associated with a reduced relapse risk in Range et al.24 The type of GnRH stimulation protocol used may also affect the ARR post-ART in terms of an increased relapse rate that may be attributed to fluctuating oestradiol levels as a result of use of a GnRH agonist protocol.9 13 Unfortunately, low patient numbers with known use of agonist or antagonist protocols in our study meant that we were unable to make any inferences. This was due in part to data collection not starting until 2006 and a number of missing data points. Current preferred practice is for the milder GnRH antagonist protocol.29 The characteristics of the patients at ART initiation suggested that, overall, the women in our study experienced relatively mild MS disease, which reflects clinician advice to plan pregnancies following a stable disease period.30 31 In total, 140 (86.4%) women had no relapses in the 12 months pre-ART initiation; the median EDSS score was 1.5 at ART initiation, and 61 (37.7%) women were DMT-naïve. Of the women who were DMT users (n=101), over half (55.4%) used interferon beta-1a, rather than a high-efficacy treatment, in part related to availability of the drug. One of the recommendations described in the report by Sparaco et al was that ART treatment should ideally be considered in women with stable MS disease, achieved by DMT use before starting the ART cycle, to reduce the risk of relapse.8 A comprehensive review of family planning considerations has been published by Krysko et al, and it provides guidance on DMT use during pregnancy and breastfeeding, thereby balancing the desire for disease stability with the safety of the newborn.4 The apparent lack of disease progression in the months following ART initiation in our study could help with DMT treatment decisions before ART initiation and consideration can be given to the continued use of DMTs during pregnancy. Family planning decisions between patients and clinicians should begin early and be revisited regularly to maximise the benefits and minimise the risks of continuing DMT treatment up to, and during pregnancy. A limitation of our study was the relatively small number of patients, but this study currently represents the largest and only nationwide population study reported to cover all women with relapsing-remitting MS from Denmark who have undergone ART treatment. The ARR analysed at 3 months post-ART initiation is the most clinically relevant because of the increased hormonal load received as part of the ART treatment. The analyses undertaken at this time point were limited by small patient numbers at 3 months and could not be stratified for ART success/failure at this time point due to data protection regulations. Furthermore, interpretation of our study may be complicated by the inclusion of women with less active disease, although this does reflect current guidance, which recommends that pregnancy should be delayed for at least a year until reasonable disease control has been achieved.30 31 Our findings with respect to DMT use pre-ART initiation did not account for the potential influence of treatment indication bias. In addition, with respect to DMT discontinuation/continuation, the results could not be stratified further by ART success owing to small sample sizes/relapse counts. Patients were included in the study until 2018. Future studies would benefit from including patients from more recent years, thereby adding more patients to the cohort and increasing the statistical certainty. Conclusions Danish women with relapsing-remitting MS did not, on average, experience increased relapse activity at 3 or 9 months post-ART initiation compared with 12 months prior. Stratified by ART outcome and pre-ART DMT use, relapse counts in subgroups became small; among women continuing DMT at ART initiation, a statistically nonsignificant ARR increase was observed at 3 months post-ART. Women with disease activity pre-ART initiation may have a potentially elevated relapse risk post-ART initiation. Supplementary material Acknowledgements Claire Snaith, PhD, of Springer Health+, Springer Healthcare Ltd., UK, provided medical writing support, which was funded and supported by Merck KGaA, Darmstadt, Germany, in accordance with the Good Publication Practice 2022 guidelines. The authors would like to acknowledge all MS clinics in Denmark for their data collection efforts and the Danish Multiple Sclerosis Society for supporting the management of the Danish Multiple Sclerosis Registry. Footnotes Funding: This work was supported by Merck (CrossRef Funder ID: 10.13039/100009945). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Data availability free text: The data underlying this article cannot be shared publicly owing to data protection regulations. All data are stored in a protected server environment at Statistics Denmark and can be accessed only by researchers authorised by Statistics Denmark and approved by the Danish Multiple Sclerosis Registry board. Data availability statement Data may be obtained from a third party and are not publicly available. References Associated Data Supplementary Materials Data Availability Statement Data may be obtained from a third party and are not publicly available.